Skip to main navigation menu Skip to main content Skip to site footer
DOI:
https://doi.org/10.57187/5371

Original article

Vol. 156 No. 11 (2026)

National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany

Cite this as:
Swiss Med Wkly. 2026;156:5371
Published
16.11.2026

Summary

STUDY AIMS: Prolonged low-dose antithrombotic and anti-inflammatory therapies have been shown to reduce cardiovascular events and are guideline-recommended in patients with coronary artery disease at high ischaemic risk. However, their real-world dispensing patterns at the population level remain insufficiently characterised. This study aimed to quantify national dispensing volumes and compare the use of these therapies in Switzerland and Germany between 2022 and 2024.

METHODS: We analysed national pharmaceutical delivery data from Switzerland and outpatient prescription data from Germany for low-dose monotherapy products containing aspirin (100 mg), clopidogrel (75 mg), prasugrel (5 mg and 10 mg), ticagrelor (60 mg and 90 mg), rivaroxaban (2.5 mg) and colchicine (0.5 mg in Germany, 1 mg in Switzerland). Drug utilisation was standardised as the number of tablets per 1000 persons per year. This metric reflects population-level exposure: based on epidemiological data indicating a substantial burden of cardiovascular disease and evidence that a relevant proportion of these patients may qualify for intensified long-term preventive therapy, dispensing volumes of long-term antithrombotic and anti-inflammatory therapies might be expected to reach a meaningful fraction of aspirin use (>10%). Values substantially below this illustrative threshold may suggest limited population-level uptake.

RESULTS: Aspirin 100 mg was the most frequently dispensed drug in both Switzerland and Germany (both >8000 tablets/1000 persons/year). Clopidogrel ranked second in both countries. Ticagrelor (60 mg and 90 mg) was more frequently dispensed in Switzerland, whereas prasugrel 10 mg was more frequently dispensed in Germany. However, absolute use of both agents remained low (all <500 tablets/1000 persons/year). Rivaroxaban 2.5 mg was the only agent that showed a consistent increase over time (+54.4% Switzerland; +40.4% Germany), although overall dispensing remained modest (538–577 tablets/1000 persons/year). Colchicine use was low in both countries (124–163 tablets/1000 persons/year). Across both countries, the combined dosing-adjusted dispensing volume of intensified long-term antithrombotic and anti-inflammatory therapies was close to or below the illustrative 10% benchmark relative to aspirin use, reaching 10.1% in Germany and 4.5% in Switzerland, suggesting limited population-level uptake, particularly in Switzerland.

CONCLUSION: Despite minor country-specific differences in cardiovascular disease prevalence, the observed dispensing patterns suggest that the population-level uptake of low-dose antithrombotic and anti-inflammatory therapies may be lower than expected when interpreted relative to aspirin.

References

  1. 1. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010 Sep 22;304(12):1350-1357. doi:10.1001/jama.2010.1322
  2. 2. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine. 2015 May 7;372(19):1791-1800. doi:10.1056/NEJMoa1500857
  3. 3. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017 Oct 5;377(14):1319-1330. doi:10.1056/NEJMoa1709118
  4. 4. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine. 2014 Dec 4;371(23):2155-2166. doi:10.1056/NEJMoa1409312
  5. 5. Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. The Lancet. 2020 Oct;396(10257):1079-1089. doi:10.1016/S0140-6736(20)31791-8
  6. 6. Jang Y, Park SD, Lee JP, Choi SH, Kong MG, Won YS, et al. One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial. EuroIntervention. 2025 Jul;21(14):e796-e809. doi:10.4244/EIJ-D-25-00331
  7. 7. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine. 2005 Apr 21;352(16):1685-1695. doi:10.1056/NEJMra043430
  8. 8. Buckley LF, Chebrolu B, Al Zaria M, Blankstein R, Libby P, Weber BN. Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States. JACC: Advances. 2025 Mar;4(3):101622. doi:10.1016/j.jacadv.2025.101622
  9. 9. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019 Dec 26;381(26):2497-2505. doi:10.1056/NEJMoa1912388
  10. 10. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020 Nov 5;383(19):1838-1847. doi:10.1056/NEJMoa2021372
  11. 11. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024 Sep 29;45(36):3415-3537. doi:10.1093/eurheartj/ehae177
  12. 12. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023 Oct 12;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
  13. 13. Kunz M, Daudí AE, Kieble M, Laufs U, Götzinger F, Boeddinghaus J, et al. Temporal trends in the prescription of low-dose antithrombotic and anti-inflammatory therapies in Germany (2022–2024). Clinical Research in Cardiology. 2026 Aug;115(8):1351-1361. doi:10.1007/s00392-025-02761-x
  14. 14. Compendium. Fachinformation COLCTAB Tabl 1 mg [Internet]. Available from: https://compendium.ch/product/1481648-colctab-tabl-1-mg
  15. 15. Bundesamt für Statistik. Ständige Wohnbevölkerung nach Postleitzahl, Staatsangehörigkeitskategorie, Geschlecht, Altersklasse und Zivilstand, 2010-2023. [Internet]. 2019. doi:10.32614/cran.package.bfs Available from: https://www.bfs.admin.ch/asset/de/32229177
  16. 16. Federal Ministry of Health. Federal Ministry of Health [Internet]. Available from: https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/mitglieder-und-versicherte
  17. 17. Schweizer Monitoring-System Sucht und nichtübertragbare Krankheiten. Herz-Kreislauf-Erkrankungen: Prävalenz (Alter: 15+) [Internet]. Available from: https://ind.obsan.admin.ch/indicator/monam/herz-kreislauf-erkrankungen-praevalenz-alter-15
  18. 18. Welsh RC, Gouda P, Dover D, Bainey KR, McAlister FA, Kaul P. Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease. Atherosclerosis. 2024 Jun;393:117486. doi:10.1016/j.atherosclerosis.2024.117486
  19. 19. De Luca L, Formigli D, Meessen J, Uguccioni M, Cosentino N, Paolillo C, et al. COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. European Heart Journal - Quality of Care and Clinical Outcomes. 2021 Sep 16;7(5):513-520. doi:10.1093/ehjqcco/qcaa054
  20. 20. Bradley SM, Hess GP, Stewart P, Armstrong EJ, Farmer SA, Wasfy JH, et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart. 2017 Apr;4(1):e000580. doi:10.1136/openhrt-2016-000580
  21. 21. Lee KY, Hwang BH, Choo EH, Lim S, Kim CJ, Kim JJ, et al. Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria. Frontiers in Cardiovascular Medicine. 2022 Nov 17;9:1017533. doi:10.3389/fcvm.2022.1017533
  22. 22. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European Heart Journal. 2015 May 14;36(19):1163-1170. doi:10.1093/eurheartj/ehu505
  23. 23. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020 Jan 14;41(3):407-477. doi:10.1093/eurheartj/ehz425
  24. 24. Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, et al. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 2024 Jan;24(1):117-127. doi:10.1007/s40256-023-00620-6
  25. 25. Magnuson EA, Li H, Wang K, Vilain K, Shafiq A, Bonaca MP, et al. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology. 2017 Aug;70(5):527-538. doi:10.1016/j.jacc.2017.05.063
  26. 26. Streuli Pharma AG. COLCTAB Tabl 1 mg Streuli Pharma AG Compendium [Internet]. Available from: https://compendium.ch/product/1481648-colctab-tabl-1-mg/mpro
  27. 27. U.S. Food and Drug Administration FDA. 2023 OND Annual Report - Breaking Barriers to Advance Public Health. 2024 Apr.
  28. 28. Lunzer R, Delle-Karth G, Zeitlinger M, Prager M, Pracher LM. Colchicin – Phönix aus der Asche. Wiener klinische Wochenschrift. 2025 Feb;137(S1):1-33. doi:10.1007/s00508-024-02490-7
  29. 29. Deutsche Apotheker Zeitung. Erstmals Xarelto-Generika im Handel [Internet]. 2024. Available from: https://www.deutsche-apotheker-zeitung.de/news/artikel/2024/04/18/erstmals-xarelto-generika-im-handel
  30. 30. Bundespatentgericht. Urteil vom 17. Januar 2025 [Internet]. Available from: https://www.bundespatentgericht.ch/fileadmin/entscheide/O2023_007-Urteil_2025-01-17.pdf
  31. 31. Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. European Journal of Preventive Cardiology. 2025 Aug 25;32(11):1001-1015. doi:10.1093/eurjpc/zwae281
  32. 32. Giacoppo D, Gragnano F, Watanabe H, Kimura T, Kang J, Park KW, et al. P2Y 12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025 Jun 4;389:e082561. doi:10.1136/bmj-2024-082561
  33. 33. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. Circulation: Cardiovascular Interventions. 2026 Jun;19(6):e016280. doi:10.1161/CIRCINTERVENTIONS.125.016280
  34. 34. Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. The Lancet. 2021 Jun;397(10293):2487-2496. doi:10.1016/S0140-6736(21)01063-1
  35. 35. Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. The Lancet. 2024 May;403(10439):1866-1878. doi:10.1016/S0140-6736(24)00473-2
  36. 36. Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr;151(13):e771-e862. doi:10.1161/CIR.0000000000001309
  37. 37. Piccolo R, Calabrò P, Carrara G, Simonetti F, Varricchio A, Attisano T, et al. Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC. 2025 Dec;86(23):2352-2367. doi:10.1016/j.jacc.2025.08.040
  38. 38. Bangalore S, Sinha SK, Singh R, Parida AK, Mody R, Abhaichand R, et al. Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial. JAMA Cardiology. 2026 Apr 1;11(4):369-377. doi:10.1001/jamacardio.2025.5057
  39. 39. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 2019 Oct 17;381(16):1524-1534. doi:10.1056/NEJMoa1908973

Most read articles by the same author(s)

<< < 1 2